ADAPTATION OF CAPSCAN TECHNOLOGY TO HEMATOPOIETIC ASSAYS

描述（从申请人的摘要中获得）：The Hipple 癌症研究 公司 发达 专利 技术 （CapScanTM） 为了定量微毛细管内的颗粒， 包括肿瘤细胞集落。 Hipple也是基于微毛细管的 用于研究性人类骨髓毒性试验的造血测定 剂. 自动化菌落计数将有助于更快，更少 昂贵的骨髓毒性评估，与现代疗效保持同步 屏幕，（即， 体外癌细胞系组），因此， 新 抗癌抗艾滋病 具有良好治疗效果的药物 指数， 而 比功效， 将是 选择发展。 在 第一阶段，我们将确定CapScanTM的可行性 技术自动化 人的菌落定量 造血祖细胞（CFU-CM和BFU-E）。 在第二阶段，我们将 开发所需的软件和硬件调整， 第一阶段的研究，并将自动化扩展到小鼠造血 集落和需要特殊染色的造血集落 用于检测（CFU-Meg）。如果成功，这将标志着第一个 开发用于造血细胞自动计数的技术 每年有超过10，000种化合物在抗癌中被筛选出来， 药物发现计划，很明显，有许多 技术的商业应用机会。

DESCRIPTION (Obtained from the applicant's abstract): The Hipple Cancer Research Corporation developed patented technology (CapScanTM) for quantitating particles inside microcapillary tubes, includingtumor cell colonies. Hipple also pioneered microcapillary-based hematopoietic assays for human myelotoxicity testing of investigational agents. Automated colony counting would facilitate faster and less expensive myelotoxicity evaluations, keeping pace with modern efficacy screens, (i.e., in vitro cancer cell lines panels), so that new anti-cancer and anti-HIV agents with favorable therapeutic indices, rather than efficacies, would be selected for development. In Phase I we will determine the feasibility of adapting CapScanTM technologies to automated quantitation of colonies of human hematopoietic progenitors (CFU-CM and BFU-E). In Phase II, we will develop the required software and hardware adaptations indicated by the PhaseI research, and extend the automationto murine hematopoietic colonies and to hematopoietic colonies that requirespecial stains fordetection (CFU-Meg). Ifsuccessful, this would mark the first technology developed for automated counting of hematopoietic colonies.With over 10,000 compounds screened each year in anti-cancer drug discoveryprograms, it is obvious that there are numerous opportunities for commercial application of the technology.